Key result
Over time, TAVR with Evolut PRO/PRO+ showed improved 30-day device success and early safety, with fewer pacemaker implantations.
Why the study?
Data regarding the impact of continuous improvements in TAVR techniques and technology on outcomes in large real-world settings remain limited.
Does transcatheter aortic valve replacement with Evolut PRO/PRO+ self-expanding valves improve procedural outcomes over time in patients undergoing transfemoral TAVR?
Observational (n=1,616)
Yes
Does transcatheter aortic valve replacement with Evolut PRO/PRO+ self-expanding valves improve procedural outcomes over time in patients undergoing transfemoral TAVR?
Procedural outcomes for TAVR with Evolut PRO/PRO+ self-expanding valves have improved over time, with higher device success and fewer complications despite treating more heavily calcified anatomies.
Answers are grounded in this paper and cite their sources.
Improved TAVR outcomes with Evolut PRO/PRO+ over time support iterative device use; leaves open generalizability beyond this cohort.
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P <0.001) and more moderate or heavy valve calcification (Q1–4, 80%, 80%, 82%, 88%; P =0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1–4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P =0.023) and early safety (Q1–4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P <0.001), with fewer permanent pacemaker implantations (Q1–4: 15.3%, 20.0%, 12.1%, 11.6%; Cochran-Armitage P =0.023) and residual mild or greater paravalvular leaks (Q1–4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P <0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. Despite the treatment of heavier calcified anatomies, procedural outcomes are improving over time with less need for pacemaker implantation and less significant paravalvular leaks.
No takes yet. Share an insight, caveat, or question.
Scotti et al. (2023) conducted an observational in Aortic valve disease (n=1,616). Transfemoral TAVR with Evolut PRO/PRO+ vs. Earlier procedural quartiles was evaluated on Temporal trends in TAVR outcomes including 30-day device success and early safety. Over time, TAVR with Evolut PRO/PRO+ showed improved 30-day device success and early safety, with fewer pacemaker implantations.
Synapse has enriched 10 related papers. Consider them for comparative context: